Earnings ·
GSK reports Q3 sales of £8.9 billion and declares 17p dividend
GSKGSK plc
GSK reported third-quarter total sales of £8.9 billion, a 4% increase at actual exchange rates (AER) and 5% at constant exchange rates (CER). Specialty Medicines drove growth with sales rising 15% to £3.9 billion, while Vaccines declined 2% to £2.6 billion. Core operating profit grew 5% to £3.08 billion, but total operating profit fell 16% due to £328 million in restructuring charges related to the Accelerate Growth programme. The company reaffirmed its full-year 2026 guidance for turnover growth of 3% to 5% and core earnings per share growth of 7% to 9%. GSK declared a quarterly dividend of 17p per share, bringing the expected full-year payout to 70p.